Endocrine Abstracts

This retrospective cohort study evaluates the real-world efficacy and safety of GLP-1 receptor agonists in type 1 diabetes management. Data from 38 patients at Beaumont Hospital, Dublin, were analyzed for clinical outcomes and safety. Key outcomes included changes in HbA1c, weight, BMI, blood pressure and lipids. Safety data included episodes of diabetic keto-acidosis (DKA) or severe hypoglycaemia. Of the 38 patients 13 were male and 25 were female. The mean age was 47 years old (SD = 11.29). The mean duration of diabetes was 27 years (SD = 11.57). The mean HbA1c was 63.8 mmol/mol (SD = 12.13) with a reduction of 4.24mmol/mol (SD = 12.54). The average reduction in weight was 8.6kg (SD = 9.50). The mean BMI of the group was 34 (SD = 4.58) with a reduction of 2 (SD = 3.92). There was one episode of DKA (post-surgery), and no severe hypoglycaemia. The mean duration of therapy was 27 months (SD = 14.96). All patients were using semaglutide except one, using dulaglutide. Systolic BP reduced by 7.3mmHg (SD = 22.37), diastolic BP increased by 1.5mmHg (SD = 9.85). The was an average reduction in LDL of 0.35mmol/l (SD = 0.50). GLP-1 receptor agonists improved glycemic control, weight, and cardiovascular risk markers in type 1 diabetes; further large-scale studies are warranted.